



Express Mail Certificate No.: EL964437986US

Date of Mailing: 8 October 2003

Attorney Docket No. P32555D2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Conley et al.

Divisional of Serial No.: 09/911,905

Previous Art Unit: 1615

Filed: Herewith

Previous Examiner: R. Bennett

For: NOVEL METHOD OF TREATMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Applicants direct the Examiner's attention to the following table of copending applications. Although all of these applications are being submitted in one form or another, the relationship between the WIPO publication, the pending U.S. application, the published application, and the internal docket number are set forth in a manner believed to better clarify their position to the Examiner. Where the applications are pending, with amended claims from the US publications, those claims are attached herewith.

US Application No.	WIPO Publication No.	Examiner	Docket No.
USSN 08/722,259 (US-2001-0043926A1)	WO 97/09042	J. Goldberg	P50383X2
USSN 09/788,948 (US-2001-0038838A1)		D. Jagoe	P50383X2D1

Divisional of Serial No.: 09/911,905

Previous Art Unit No.: 1615

US Application No.	WIPO Publication No.	Examiner	Docket No.
USSN 08/993,898	WO 94/16696	J. Goldberg	P30580C3X2
USSN 10/321,875 (US-2003-0109503)		J. Goldberg	P30580C4
USSN 09/544,019		R. Bennett	P32554
USSN 10/115,700 (US-2002-0168405A1)		R. Bennett	P32554D1
US Pat. 6,294,199 (USSN 09/544,417)		R. Bennett	P32555
USSN 09/911,905 (US-2002-0001616A1) (Divisional of this series)		R. Bennett	P32555D1
USSN 09/689,483		R. Bennett	P32685
USSN 09/971,560		R. Bennett	P32685C1
USSN 09/974,596 (US-2002-0128251A1) (allowed)	WO 02/30392	M. Young	P32687
USSN 09/974,572		M Young	P32688
USSN 10/462,066 (allowed)		M Young	P32688C1
USSN 09/355,645	WO 98/35672	B. Fubara	P31740
USSN 10/302,199 (US-2003-012487A1)		B. Fubara	P31740D1
USSN 08/945,365	WO 96/34605	J. Goldberg	P31167X1
USSN 10/043,437 (US-2002-0099044A1)		J. Goldberg	P31167X1C1
USSN 10/069,681	WO 01/13883	(not yet assigned)	P32396
U.S. Pat. 5,910,322 (USSN 08/776,909)	WO 96/04908	B. Seidleck	P31707
U.S. Pat. 6,299,903 (USSN 09/251,597)		B. Seidleck	P31707D1
USSN 10/412,177		(not yet assigned)	P33029
US 6,544,558 (USSN 10/016,041)	WO 92/19227	J. Spear	P30048C3D3

Divisional of Serial No.: 09/911,905
Previous Art Unit No.: 1615


Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form, separate PTOL 1449 form.

This submission does not represent that a complete search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 19-2570.

Respectfully submitted,



Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090
N:\DLDOA\US\32555\DI\DI\IDS Letter.doc

INFORMATION DISCLOSURE CITATION

Atty. Docket No. P3255D2	Appln. No. Divisional of 09/911,905
Applicant Conley et al.	
Filing Date Herewith	Previous Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	USSN 08/722,259		Burch			10/08/97
	USSN 09/788,948		Burch et al.			02/20/01
	USSN 08/993,898		Smith et al.			12/18/97
	USSN 10/321,875		Smith et al.			12/17/02
	USSN 09/544,019		Conley et al.			04/06/00
	USSN 10/115,700		Conley et al.			04/04/02
	USSN 09/911,905		Conley et al.			07/24/01
	USSN 09/689,483		Storm et al.			10/12/00
	USSN 09/971,560		Storm et al.			10/05/01
	USSN 09/974,596		Storm et al.			10/10/01
	USSN 10/462,066		Storm et al.			06/13/03
	USSN 10/302,199		Mention et al.			11/22/02
	USSN 10/043,437		Bax et al.			01/11/02
	USSN 10/069,681		Barges et al.			08/17/00
	USSN 10/412,177		Roush et al.			04/11/03

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce	

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	P32555D1D1	Appln. No.	Divisional of 09/911,905
Applicant	Conley et al.		
Filing Date	Herewith	Previous Group:	1615

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	US 4,110,165	08/29/78	Cole et al.			
	US 4,282,202	08/04/81	Dowrick			
	US 4,301,149	11/17/81	Crowley			
	US 4,441,609	04/10/84	Crowley			
	US 4,525,352	06/25/85	Cole et al.			
	US 4,537,887	08/27/85	Rooke et al.			
	US 4,673,637	06/16/87	Hyman			
	US 4,950,484	08/21/90	Olthoff et al.			
	US 5,051,262	09/24/91	Panoz et al.			
	US 5,007,790	04/16/91	Shell			
	US 5,133,974	07/28/92	Paradissis et al.			
	US 5,158,779	10/29/92	Gergely et al.			
	US 5,225,197	07/06/93	Bolt et al.			
	US 5,407,686	04/18/95	Patel et al.			
	US 5,445,829	08/29/95	Paradissis et al.			
	US 5,487,901	01/30/96	Conte et al.			
	US 5,500,227	03/19/96	Oshlack et al.			
	US 5,582,837	12/10/96	Shell			
	US 5,650,169	07/22/97	Conte et al.			
	US 5,670,170	09/23/97	Grimmett et al.			
	US 5,681,583	10/28/97	Conte et al.			
	US 5,690,959	11/25/97	Palepu et al.			
	US 5,733,577	03/31/98	Myers et al.			
	US 5,738,874	04/14/98	Conte et al.			
	US 5,741,524	04/21/98	Stanisforth et al.			
	US 5,814,337	09/29/98	Merrifield et al.			
	US 5,849,330	12/15/98	Marvola et al.			
	US 5,851,550	12/22/98	Martin et al.			
	US 5,858,412	01/12/99	Stanisforth et al.			
	US 5,861,172	01/19/99	Martin et al.			
	US 5,910,322	06/08/99	Rivett et al.			
	US 5,962,022	10/05/99	Bolt et al.			
	US 5,972,389	10/26/99	Shell et al.			
	US 6,051,254	04/18/00	Merrifield et al.			
	US 6,051,255	04/18/00	Conley et al.			
	US 6,077,536	06/20/00	Merrifield et al.			
	US 6,110,497	08/29/00	Martin et al.			
	US 6,126,969	10/03/00	Shah et al.			
	US 6,136,345	10/24/00	Grimmett et al.			
	US 6,177,421 B1	01/23/01	Moir et al.			

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	P32555D1D1	Appln. No.	Divisional of 09/911,905
Applicant	Conley et al.		
Filing Date	Herewith	Previous Group:	1615

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	US 6,183,778 B1	02/06/01	Conte et al.			
	US 6,183,780 B1	02/06/01	Van Balken et al.			
	US 6,214,359 B1	04/10/01	Bax			
	US 6,294,199 B1	09/25/01	Conley et al.			
	US 6,294,200 B1	09/25/01	Conte et al.			
	US 6,299,903 B1	10/09/01	Rivett et al.			
	US 6,340,475 B2	01/22/02	Shell et al.			
	US 6,352,720 B1	03/05/02	Martin et al.			
	US 6,358,528 B1	03/19/02	Grimmett et al.			
	US 6,372,255 B1	04/16/02	Saslawski et al.			
	US 6,399,086 B1	06/04/02	Katzhendler et al.			
	US2001/0018070 A1	08/30/01	Shell et al.			
	US2001/0026809 A1	10/04/01	Oshlack et al.			
	US2001/0038838 A1	11/08/01	Burch			
	US2001/0043926 A1	11/22/01	Burch			
	US2001/0046984 A1	11/29/01	Rudnic			
	US2001/0048944 A1	12/06/01	Rudnic et al.			
	US2002/0001616 A1	01/03/02	Conley et al.			
	US2002/0004071 A1	01/10/02	Cherukuri			
	US2002/0004499 A1	01/10/02	Rudnic et al.			
	US2002/0006433 A1	01/17/02	Davidson et al.			
	US2002/0064562 A1	05/30/02	Martin et al.			
	US2002/0086056 A1	07/04/02	Grimmett et al.			

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	EP 0080862A1 ✓	06/08/83	EPO			
	EP 0080862B1 ✓	9/25/85	EPO			
	EP 0131147B1 ✓	01/16/85	EPO			
	EP 0131147B2 ✓	12/04/96	EPO			
	EP 0222914A1 ✓	05/27/87	EPO			
	EP 0234670A2 ✓	09/02/87	EPO			
	EP 0281200A ✓	12/04/96	EPO			
	EP 0389177A ✓	09/0788	EPO			
	EP 0396335A1 ✓	11/07/90	EPO			
	EP 1044680A ✓	10/18/00	EPO			
	GB 1,508,977 ✓	04/26/78	Great Britain			
	GB 2,005,538 A ✓	04/25/79	Great Britain			
	HU 205 611 B ✓	04/29/91	Hungary			
	WO 00/03695 A1 ✓	01/27/00	WIPO			

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	P32555D1D1	Appln. No.	Divisional of 09/911,905
Applicant	Conley et al.		
Filing Date	Herewith	Previous Group:	1615

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
		WO 00/12088 A1	03/09/00	WIPO			
		WO 00/23045	04/27/00	WIPO			
		WO 00/41478	07/20/00	WIPO			
		WO 00/44353	08/03/00	WIPO			
		WO 00/61116	10/19/00	WIPO			
		WO 01/00177 A1	01/04/01	WIPO			
		WO 01/56544 A2	08/09/01	WIPO			
		WO 01/62231 A1	08/30/01	WIPO			
		WO 01/80824 A2	11/01/01	WIPO			
		WO 91/15197 A1	10/17/91	WIPO			
		WO 92/19227 A2 ✓	11/12/92	WIPO			
		WO 93/00898 A1	01/21/93	WIPO			
		WO 94/06416	03/31/94	WIPO			
		WO 94/16696	08/04/94	WIPO			
		WO 94/27557	12/08/94	WIPO			
		WO 94/27600 A1	12/08/94	WIPO			
		WO 95/20946	08/10/95	WIPO			
		WO 95/25516 A1	09/28/95	WIPO			
		WO 95/28148	10/26/95	WIPO			
		WO 95/28927	11/02/95	WIPO			
		WO 95/33487 A1	12/14/95	WIPO			
		WO 96/04907 A1	02/22/96	WIPO			
		WO 96/04908	02/22/96	WIPO			
		WO 96/07408	03/14/96	WIPO			
		WO 96/34605 A1	11/07/96	WIPO			
		WO 97/09042	03/13/97	WIPO			
		WO 98/05305	02/12/98	WIPO			
		WO 98/07424 A1	02/26/98	WIPO			
		WO 98/22091	05/28/98	WIPO			
		WO 98/35672	08/20/98	WIPO			
		WO 98/40054 A1	09/17/98	WIPO			
		WO 98/42311 A1	10/01/98	WIPO			
		WO 99/25343	05/27/99	WIPO			
		WO 99/47125	09/23/99	WIPO			
		WO 99/62910	12/09/99	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	1996 MIMS Annual, "Augmentin," Twentieth Edition, May 1995, pgs. 8-476 to 8-477
	Amendola et al., "Pediatric suspension of amoxycillin and clavulanic acid in the treatment of bacterial infections of the upper respiratory tract and ear", Minerva Pediatrica, February 1989, 41(2), pgs. 97-103 (English abstract)
	Appelbaum, 1996, "Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae," Ped. Inf. Dis. J., 15(10): 932-939.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	P32555D1D1	Appln. No.	Divisional of 09/911,905
Applicant	Conley et al.		
Filing Date	Herewith	Previous Group:	1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Arancibia et al., 1987, "Pharmacokinetics and bioavailability of a controlled release amoxicillin formulation," Int. J. of Clin. Pharm., Ther. and Tox., 25(2): 97-100.
	Arguedas et al., "In-vitro activity of cefprozil (BMV 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid", J. Antimicrob. Chemother., 1991, 27, pgs. 311-318
	Astruc, "Effectiveness and Safety of a New Formulation Containing 100 mg amoxicillin - 12.5 mg clavulanic acid in infants with acute otitis media", Annales De Pédiatrie, February 1992, vol. 39, no. 2, 142-148 (with translation)
	Aulton et al., "The Mechanical Properties of Hydroxypropylmethylcellulose Films Derived from Aqueous Systems", Drug Development and Industrial Pharmacy, 1981, 7(6), pgs. 649-668
	Ball et al., "Clavulanic Acid and Amoxycillin: A Clinical, Bacteriological, and Pharmacological Study", The Lancet, March 22, 1980, Pgs 620-623
	Baron et al., "Antimicrobial therapy in acute otitis media", Traitement Antibiotique de L'Otite Moyenne Aiguë, Ann Pédiatr, 1991, 38(8), pgs 549-555 (with translation of abstract)
	Barry et al., "Effect of Increased Dosages of Amoxycillin in Treatment of Experimental Middle Ear Otitis Due to Penicillin-Resistant Streptococcus pneumoniae", Antimicrobial Agents and Chemotherapy, August 1993, Vol 37, No. 8, pgs. 1599-1603
	Beghi et al., "Efficacy and Tolerability of Azithromycin versus Amoxicillin/Clavulanic Acid in Acute Purulent Exacerbation of Chronic Bronchitis", Journal of Chemotherapy, 1995, 7(2), pgs 146-152
	Behre et al., "Efficacy of Twice-Daily Dosing of Amoxycillin/Clavulanate in Acute Otitis Media in Children", Infection, 1997, 25(3), pgs. 163-166
	Berry et al., "Bactericidal and Morphological Effects of Amoxicillin on Helicobacter pylori", Antimicrobial Agents and Chemotherapy, Aug 1995, vol 39(8), pgs 1859-1861
	Berry et al., "Bacteriological Efficacies of Three Macrolides Compared with Those of Amoxicillin-Clavulanate against Streptococcus pneumoniae and Haemophilus influenzae", Antimicrobial Agents and Chemotherapy, 1998, vol. 42(12), pgs 3193-3199
	Berry et al., "Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection", J. Antimicrob. Chemother., Dec. 2000, no 45, supplement S1 pgs 87-93
	Berry et al., "Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection, J. Antimicrob. Chemother., vol 45, supplement S1, pgs 79-85
	Bottenfield et al., "Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin®) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae," Pediatr Infect. Dis. J., 1998, vol. 17(10), pp. 963-968
	Brooks et al., "Pleuromutilins, Part 1: The Identification of Novel Mutilin 14-Carbamates", Bioorganic and Medicinal Chemistry 9, 2001, pgs 1221-1231.
	Bronner et al., "Ex vivo pharmacodynamics of 1.1 g IV amoxicillin-clavulanic acid against β -lactamase positive E. coli in a Yucatan micropig model that mimics human pharmacokinetics (2.2 g IV)", Antibiotiques, 2001, 3: 91-98 (Translation Included)
	Burgess et al., "Uptake of clavulanic acid across rat jejunal segments in vitro", J. Physiology, vol 482, pg 41P
	Caillon et al., May 1998, "Dynamics of the bacteriocide activity of ofloxacin-amoxicillin and ofloxacin-clavulanic acid against pathogen bacteria of the respiratory tract", Pathologie Biologie, 36(5), pgs. 414-419.
	Calver et al., "Amoxicillin/Clavulanate (A/C) BID vs A/C TID in the Treatment of Lower Respiratory Tract Infections (LRTI)", Abstracts of the 35th ICAAC, 1995, pg 334
	Calver et al., "Augmentin BID Versus Augmentin TID in the Treatment of Lower Respiratory Tract Infections", Can. J. Infect Dis., July 1995, Vol 6 Suppl C, Abstract No. 0338, pg 239C ABSTRACT
	Calver et al., "Dosing of Amoxicillin/Clavulanate Given Every 12 Hours is as Effective as Dosing Every 8 Hours for Treatment of Lower Respiratory Tract Infection", Clinical Infectious Disease, April 1997, 24, pgs 570-574
	Caron et al., "Effects of Amoxicillin-Clavulanate Combination on the Motility of the Small Intestine in Human Beings", Antimicrobial Agents and Chemotherapy, June 1991, Vol. 35 No. 6, pgs 1085-1088
	Cars, "Efficacy of Beta-lactam Antibiotics: Integration of Pharmacokinetics and Pharmacodynamics", Diagn Microbiol Infect Dis, 1997, 27 pgs 29-33
	Catherall et al., "Distribution and Efficacy Studies with Ticarcillin-Clavulanic Acid (Timentin) in Experimental Klebsiella Pneumoniae Meningitis in Rabbits", Journal of Chemotherapy, 1989 supplement no 4, pgs 80-81
	Chan et al., "A Comparative Study of Amoxicillin-Clavulanate and Amoxicillin. Treatment of Otitis Media with Effusion," Archives of Otolaryngology - Head and Neck Surgery, Feb 1988, 114, pgs 142-146
	Chiou, "Critical Evaluation of the Potential Error in Pharmacokinetic Studies of Using the Linear Trapezoidal Rule Method for the Calculation of the Area Under the Plasma Level-Time Curve," 1978, J. Pharmacokinetic. Biopharm., 6(6): 539-546
	Connor et al., "High Resolution ¹ H NMR Spectroscopic Studies of the Metabolism and Excretion of Ampicillin in Rats and Amoxycillin in Rats and Man", Journal Pharm. Pharmacol. 1994, vol 46 pgs 128-134
	Cook et al., "Efficacy of Twice-Daily Amoxycillin/Clavulanate ('Augmentin-Duo' 400/57) in Mild to Moderate Lower Respiratory Tract Infection in Children", BJCP, 50(3), April/May 1996, pgs. 125-128

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	P32555D1D1	Appln. No.	Divisional of 09/911,905
Applicant	Conley et al.		
Filing Date	Herewith	Previous Group:	1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Cooper et al., "Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against β -lactamase-producing <i>Branhamella catarrhalis</i> and <i>Haemophilus influenzae</i> ", <i>Journal of Antimicrobial Chemotherapy</i> , 1990, vol. 26, pgs. 371-380
	Craig et al., "Killing and Regrowth of Bacteria in Vitro: A Review", <i>Scand J Infect Dis.</i> , 1991, Suppl 74, pgs 63-70
	Craig, "Antimicrobial Resistant Issues of the Future", <i>Diagn Microbiol Infect Dis</i> , 1996, 25, pgs. 213-217
	Craig, "Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men", <i>Clinical Infectious Diseases</i> , January 1998, 26, Pgs 1-12
	Craig et al., "Pharmacokinetics and pharmacodynamics of antibiotics in otitis media", <i>Pediatr Infect Dis J</i> , 1996, 15(10), pgs.944-948 (Reprint)
	Crokaert et al., "Activities of Amoxicillin and Clavulanic Acid Combinations Against Urinary Tract Infections", <i>Antimicrobial Agents and Chemotherapy</i> , Aug 1982, Vol 22 No. 2, pgs 346-349
✓	Dagan et al., "Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media", <i>Pediatric Infectious Diseases Journal</i> , September 2001, vol 20(9), pgs 829-837
✓	Dagan et al., "Bacteriological and Clinical Efficacy of a New Amoxicillin/Clavulanate Extra Strength formulation in the Treatment of Acute Otitis Media (AOM), Abstract 107 from the 40 th ICAAC, September 17-20, 2000, pg 491
✓	Ellis-Pegler et al., "Augmentin treatment of bacterial infections in hospitalized patients", <i>New Zealand Medical Journal</i> , 1982, 95, pgs 542-545
	Everett et al., " ¹⁹ F NMR Spectroscopy Study of the Metabolites of Flucloxacillin in Rat Urine," <i>Journal of Pharm. Pharmacology</i> , 1985, vol 37, pgs 869-873.
	Everett et al., "A Study of Flucloxacillin Metabolites in Rat Urine by Two-Dimensional ¹ H, ¹⁹ F COSY NMR," <i>Journal of Pharmaceutical & Biomedical Analysis</i> , 1989, vol 7, no 3, pgs 397-403.
	Everett et al., "Spin-echo ¹ H N.M.R. spectroscopy: A new method for studying penicillin metabolism," <i>J. Chem. Soc. Chem. Commun.</i> , 1984, pgs 894-895.
	Feldman et al., "Twice-daily antibiotics in the treatment of acute otitis media: trimethoprim-sulfamethoxazole versus amoxicillin-clavulanate", <i>Can Med. Assoc. J.</i> , 1990, 142(2): 115-118
	Finch, "Pneumonia: The Impact of Antibiotic Resistance on its Management", <i>Microbial Drug Resistance</i> , Vol 1, No. 2, 1995, pgs. 149-158
	Fink et al., "A trial of orally administered Augmentin in the treatment of urinary tract infection and lower respiratory tract infection in a children's hospital", <i>Proc Eur Symp on Augmentin</i> , Scheveningen June 1982, 1983: pgs 325-333
	Flatulence, Diarrhoea, and Polyol Sweetners, <i>The Lancet</i> , December 3, 1983, Vol. II, pg 1321
	Fraschini et al., "Pharmacokinetics and Tissue Distribution of Amoxicillin plus Clavulanic Acid after Oral Administration in Man", <i>Journal of Chemotherapy</i> , 1990, 2(3), pgs 171-177
	Friedland et al., "Management of Infections caused by Antibiotic-Resistant <i>Streptococcus Pneumoniae</i> ", <i>The New England Journal of Medicine</i> , August 1994, Vol. 331, No. 6, pgs. 377-382
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: The Opinion and Order rendered on July 19, 2002 (as issued by the court)
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: The Opinion and Order rendered on July 19, 2002 (as published by West Law at 2002 WL 1802991)
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: The trial transcript of May 23, 2002 relating to the Court's decision of July 19, 2002
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: The Opinion and Order rendered April 22, 2002
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: the trial transcript of March 13, 2002, relating to the Court's decision of April 22, 2002
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: the Opinion and Order rendered February 25, 2002
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: the trial transcript of December 14, 2001, relating to the Court's decision of February 25, 2002
	Greenwood, D., "Short Communication: a type of interaction between clavulanic acid and other β -lactam antibiotics distinct from the β -lactamase inhibition effect," from Augmentin: clavulanate-potentiated amoxycillin, <i>Proceeding of the First Symposium</i> , July 3-4, 1980, pages 80-83.
	Handbook of Pharmaceutical Excipients, Third Edition, "Mannitol," 1986, Edited by Arthur H. Kibbe, Ph.D., pp 324-328
	Hannan et al., "In Vitro Activity of Gemifloxacin (SB 265805; LB 20304a) against human mycoplasmas," <i>Journal of Antimicrobial Chemotherapy</i> , 2000, vol 45, pgs 367-369.
	Heikkinen et al., "Short-term use of amoxicillin-clavulanate during upper respiratory tract infection for prevention of acute otitis media", <i>The Journal of Pediatrics</i> , Feb 1995, 126(2), pgs 313-316
	Hilton et al., 1992, "In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxycillin trihydrate," <i>Intl. J. of Pharmaceutics</i> , 86: 79-88.
	Hilton et al., 1993, "Use of Hydroxypropyl Methylcellulose Acetate Succinate in an Enteric Polymer Matrix to Design Controlled-Release Tablets of Amoxicillin Trihydrate," <i>J. Pharmaceutical Sciences</i> , 82(7): 737-743.

Examiner	Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	P32555D1D1	Appln. No.	Divisional of 09/911,905
Applicant	Conley et al.		
Filing Date	Herewith	Previous Group:	1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Hoberman et al., "Efficacy of amoxicillin/clavulanate for acute otitis media: relation to Streptococcus pneumoniae susceptibility", <i>Pediatr Infect Dis J.</i> , October 1996, 15(10), pgs. 955-962
	Hoberman et al., "Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin®) for treatment of acute otitis media in children", <i>Pediatric Infect. Dis. J.</i> , May 1997, 16(5), pgs. 463-470
	Hoffman, et al., 1998, "Pharmacodynamic and Pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form," <i>J. Controlled Release</i> , 54: 29-37.
	Hol et al., "Experimental evidence for Moraxella-induced penicillin neutralization in pneumococcal pneumonia", <i>Journal of Infectious Diseases</i> , 1994, 170, pgs 1613-1616
	Jacobsson et al., "Evaluation of Amoxicillin Clavulanate Twice Daily versus Thrice Daily in the Treatment of Otitis Media in Children", <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> , May 1993, 12(5): 319-324
	Jeffries et al., "An Initial Assessment of Augmentin for the Treatment of Paediatric Infections in General Practice", <i>The British Journal of Clinical Practice</i> , 1996, pgs. 61-66
	Ji et al., "Identification of Critical Staphylococcal Genes Using Conditional Phenotypes Generated by Antisense RNA", <i>Science Reprint</i> , September 21, 2001, vol 293, pgs 2266-2269
	Ji et al., "Regulated Antisense RNA Eliminates Alpha-Toxin Virulence in Staphylococcus aureus Infection", <i>Journal of Bacteriology</i> , November 1999, pgs 6585-6590
	Klein, "Antimicrobial Agents", <i>Therapeutics – Part V</i> , from the <u>Textbook of Pediatric Infectious Diseases, 3rd Edition, Volume II</u> , Editors R. D. Feigin and J. D. Cherry, 1992, pgs. 2179-2198
	Kucer et al., "Ampicillin-like penicillins – Amoxycillin, Epicillin, Cycloacillin, Hetacillin, Pivampicillin, Talampicillin, Bacampicillin and Metampicillin", 2) "Clavulanic Acid", <i>The Use of Antibiotics</i> , 1987, pgs. 172-195/271-286
	Lachman et al., "Tablet Granulations", <i>The Theory and Practice of Industrial Pharmacy</i> , 1986, pgs. 314-320
	Legent et al., "A Double-Blind Comparison of Ciprofloxacin and Amoxycillin/Clavulanic Acid in the Treatment of Chronic Sinusitis", <i>Chemotherapy</i> , 1994 40(Suppl. 1), 8-15
	Lerk et al., "Interaction of lubricants and colloidal silica during mixing with excipients", <i>Pharmaceutica Acta Helveticae</i> , 1977, 52(3) pgs 33-39
	Lieberman et al., "Pharmaceutical Dosage Forms – Tablets Second Edition, Revised and Expanded", 1990, vol. 2, pgs. 317-335
	Lister et al., "Rationale behind High-Dose Amoxycillin Therapy for Acute Otitis Media Due to Penicillin-Nonsusceptible Pneumococci: Support from In Vitro Pharmacodynamic Studies", <i>Antimicrobial Agents and Chemotherapy</i> , September 1997, vol. 41, no 9, pgs 1926-1932
	Mandell et al., "Beta-Lactamase Inhibitors, Antimicrobial Agents (cont.)", Goodman and Gillman's <i>The Pharmacological Basis of Therapeutics</i> , 8 th edition, The Macmillan Company, 1990, pg. 1093
	Martindale, <i>The Extra Pharmacopoeia</i> , Thirtieth Edition, "Amoxycillin" and "Clavulanic Acid," Edited by James E. F. Reynolds, The Pharmaceutical Press, 1993, pgs 115-116 and 148
	McCracken "Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics", <i>Pediatr Infect Dis J</i> , May 1995, 14(5), pgs. 424-428
	McLaren et al., "A comparison of the efficacy and tolerability of Augmentin 625 mg po bd versus Augmentin 375 mg po tds in the treatment of acute bacterial exacerbations of chronic bronchitis", <i>British Journal Clin Research</i> , 1994, 5 pgs 1-10
	Merck Index, Eleventh Edition, "Amoxycillin" and "Clavulanic Acid," Edited by S. Budavari et al., Merck & Co., Inc., 1989, pp. 612 and 2342-2343
	Mizen et al., "A Critique of Animal Pharmacokinetics", <i>Journal of Antimicrobial Chemotherapy</i> , 1988, vol 21, pgs 273-280
	Mizen et al., "Simulation of Human Serum Pharmacokinetics of Ticarcillin-Clavulanic Acid and Cefazidime in Rabbits and Efficacy Against Experimental Klebsiella Pneumoniae Meningitis", <i>Antimicrobial Agents and Chemotherapy</i> , May 1989, vol 33, no. 5, pgs 693-699
	Mizen et al., "The Influence of Uptake from the Gastrointestinal Tract and First-pass Effect on Oral Bioavailability of (Z)-alkyloxyimino Penicillins", <i>Journal of Pharm. Pharmacology</i> , 1995, vol 47, pgs 725-730
	Moonsammy et al., "Improved Safety Profile of a New Amoxicillin/Clavulanate (A/C) Adult BID Formulation Compared with the Standard A/C TID Formulation", <i>Abstracts of the 36th ICAAC</i> , Chapter 20, poster LM51, 1996, pg. 290
	Neu, "Other β -Lactam Antibiotics", <i>Principles and Practice of Infectious Diseases</i> , 1990, pgs. 257-263
	Neville, "Augmentin: An in vitro study of bacterial sensitivities to a synergistic combination", <i>New Zealand Medical Journal</i> , 1982, 95, pgs 579-581
	Nicolau et al., "Antibiotic Kinetics and Dynamics for the Clinician", <i>The Medical Clinics of North America Antimicrobial Therapy I</i> , May 1995, Vol. 79(3): 477-495
	Okhamafe et al., "Characterization of moisture interactions in some aqueous-based tablet film coating formulations", <i>Journal Pharm Pharmacol</i> , 1985, 37, pgs 385-390
	Pankuch et al., "Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci", <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 35, 883-888
	Parrott, "Densification of Powders by Concavo-Convex Roller Compactor", <i>Journal of Pharm Sciences</i> , March 1981, Vol 70(3), pgs 288-291
	Physicians' Desk Reference, 1998, 52 nd Edition, Medical Economics Co., Montvale, NJ, p. 2798-2805.
	Physicians' Desk Reference, 40 th Edition, 1986, "Amoxycillin," pp. 1315-1316.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	P32555D1D1	Appln. No.	Divisional of 09/911,905
Applicant	Conley et al.		
Filing Date	Herewith	Previous Group:	1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Pichichero, "Resistant respiratory pathogens and extended-spectrum antibiotics", American Family Physician, 1995, 52(6), pgs 1739-1746
	Prescribing for Children, British National Formulary, vol. 29, pg. 11
	Remington's Pharmaceutical Sciences, Eighteenth Edition, 1990, pp. 1304-1308, 1317-1323
	Repertorio Farmaceutico Italiano, 3rd Edition 1989, A106 to A108. (Translation Included)
	Robinson, "Amoxicillin trihydrate/Clavulanic acid potassium salt", Med. Actual. Drugs of Today, 1982, 18(5) pgs 213-219
	Ruberto et al., "Amoxycillin and Clavulanic Acid in the Treatment of Urinary Tract Infections in Children", Journal of International Medical Research, 1989, 17: 168-171
	Saarnivaara et al., "Effect of Storage on the Properties of Acetylsalicylic Acid Tablets Coated with Aqueous Hydroxypropyl Methyl-Cellulose Dispersion", Drug Develop and Ind Pharmacy, 1985, 11(2&3), pgs 481-492
	Sakellariou et al., "An evaluation of the interaction and plasticizing efficiency of the polyethylene glycols in ethyl cellulose and hydroxypropyl methylcellulose films using the torsional braid pendulum", Int Journal of Pharm, 1986, 31, pgs 55-64
	Segatore, et al., 1993, "In vitro Activity of Cefodizime (HR-221) in Combination with β -Lactamase Inhibitors," Journal of Chemotherapy, Vol. 5, No. 3, pp. 147-150.
	Slocombe et al., "In Vitro and In Vivo Activity of Temocillin", Research and Clinical Forums, vol 12, no 5, pgs 21-31.
	Staniforth et al., "Effect of food on the bioavailability and tolerance of clavulanic acid/amoxycillin combination", Journal of Antimicrobial Chemotherapy, 1982, 10, pgs 131-139
	Stein et al., "Amoxicillin-potassium clavulanate, a β -lactamase-resistant antibiotic combination", Clinical Pharmacy, Vol. 3, Nov-Dec 1984 pgs 591-599
	Sumita et al., 1991, "In vitro Synergistic Activity between Meropenem and other Beta-Lactams against Methicillin-Resistant Staphylococcus aureus," European Journal of Clinical Microbiology and Infectious Diseases, Vol. 10, No. 2, pp. 77-84.
	The Use of Antibiotics, 4th Edition, "Clinical Uses of the Drug -amoxycillin/clavulanic acid," J. B. Lippincott Company, 1987 pgs 278-279
	Therapeutic Drugs, "Clavulanate (potassium)," Dollery, 1999, pgs C253-C256
	Todd et al., "Amoxicillin/Clavulanic Acid - An Update of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use", Drugs, 1990, 39(2), pgs 264-307
	Toh, "Amoxycillin with clavulanic acid", The Australian Nurses Journal, Dec/Jan 1989, Volume 18, No. 6, p. 23, Abstract
	Tondachi et al., "Tablet Coating in an Aqueous System", Drug Develop and Ind Pharmacy, 1977, 3(3), pgs 227-240
	van Niekerk et al., "Pharmacokinetic Study of a Paediatric Formulation of Amoxycillin and Clavulanic Acid in Children", European Journal of Clinical Pharmacology, 1985, 29, pgs 235-239
	Vidal 1994, "AUGMENTIN - oral forms," 70th Edition, pgs. 132-134 (Translation Included)
	Woodnutt et al., "Acetate entry rate into portal and peripheral blood in the rabbit", Proc. Nutr. Soc., 1979, vol 38, pg 72A.
	Woodnutt et al., "Acetate Metabolism By Tissues of the Rabbit", Comp. Biochemical Physiol, 1986, vol 85B, no 2, pgs 487-490.
	Woodnutt et al., "Effect of Protein Binding on Penetration of β -Lactams into Rabbit Peripheral Lymph", Antimicrobial Agents and Chemotherapy, December 1995, vol 39, no 12, pgs 2678-2683
	Woodnutt et al., "Efficacité de l'association amoxicilline-acide clavulanique dans un modèle d'abcès sous-cutané à E. coli chez le rat après simulation de l'administration chez l'homme de 1 g/200 mg (IVD) ou de 2 g/200 mg (perfusion). La lettre de l'infectiologie de la microbiologie a la clinique". Numero hors-serie. Feb 1995, pgs 23-26
	Woodnutt et al., "Efficacy of High-Dose Amoxicillin-Clavulanate against Experimental Respiratory Tract Infections Caused by Strains of Streptococcus pneumoniae", Antimicrobial Agents and Chemotherapy, January 1999, 43(1), 35-40
	Woodnutt et al., "Evaluation of reduced dosing schedule of amoxicillin (AMX) using two pharmacodynamic modes", Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 1995, A40, p. 8
	Woodnutt et al., "Influence of simulated human pharmacokinetics on the efficacy of temocillin against a Klebsiella Pneumoniae meningitis infection in the rabbit", Journal of Chemotherapy, 1989, supplement no. 4, pgs 475-476
	Woodnutt et al., "Penetration of amoxycillin, ticarcillin and clavulanic acid into lymph after intravenous infusion in rabbits to simulate human serum pharmacokinetics", Journal of Antimicrobial Chemotherapy, 1990, vol 26, pgs 695-704
	Woodnutt et al., "Penetration of augmentin and timentin into lymph after simulation of human serum pharmacokinetics in the rabbit", J. Drug Devel. 1989, 2, Supplement 1, pgs 123-126
	Woodnutt et al., "Pharmacodynamics to Combat Resistance", Journal of Antimicrobial Chemotherapy, 2000, vol 46, Topic T1, pgs 25-31
	Woodnutt et al., "Pharmacokinetics and Distribution of Ticarcillin-Clavulanic Acid (Timentin) in Experimental Animals", Antimicrobial Agents and Chemotherapy, 1987, vol 31, no 11, pgs 1826-1830
	Woodnutt et al., "Rabbit liver acetyl-CoA synthetase", Biochem J., 1978, vol 175, pgs 757-759
	Woodnutt et al., "Simulation of Human Serum Pharmacokinetics of Cefazolin, Piperacillin, and BRL 42715 in Rats and Efficacy Against Experimental Intraperitoneal Infections", Antimicrobial Agents and Chemotherapy, July 1992, vol 36, no. 7, pgs 1427-1431
	Woodnutt et al., "Temocillin Efficacy in Experimental Klebsiella Pneumoniae Meningitis after Infusion into Rabbit Plasma To Simulate Antibiotic Concentrations in Human Serum", Antimicrobial Agents and Chemotherapy, November 1988, vol 32, no 11, pgs 1705-1709

Examiner	Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	P32555D1D1	Appln. No.	Divisional of 09/911,905
Applicant	Conley et al.		
Filing Date	Herewith	Previous Group:	1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Woodnutt et al., "Two Pharmacodynamic Models for Assessing the Efficacy of Amoxicillin-Clavulanate against Experimental Respiratory Tract Infections Caused by Strains of Streptococcus pneumoniae", Antimicrobial Agents and Chemotherapy, January 1999, vol 43, no 1, pgs 29-34

Examiner	Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce